In clinical settings, aerosolized rhIFN-γ adjunct therapy has improved inflammatory markers and clinical outcomes in patients with pulmonary TB (Gao et al., 2011), and a randomized trial of drug-resistant TB reported faster culture conversion and better outcomes with IFN-γ add-on therapy (Suárez-Méndez et al., 2004). The gene discussed is IFNG; the disease is tuberculosis.